Anti-CTLA4 Antibody [BNI3] (A279848)

Anti-CTLA4 Antibody [BNI3]

Mouse monoclonal [BNI3] antibody to CTLA4.

IP, Flow Cytometry, ELISA, IHC-Fr, IF

FC 1: Neat - 1:10, IHC-Fr 2: 5 µg/ml - 50 µg/ml, Mouse anti Human CD152 antibody, clone BNI3 can be used as the capture antibody in a bridging ELISA with HCA335 as the detection antibody.Protocol: PK bridging ELISAProtocol: ADA bridging ELISA, Use 10µl of the suggested working dilution to label 1x10⁶ cells in 100µl

Human

Human CTLA-4/Human IgG heavy chain fusion protein.

Mouse

Monoclonal

BNI3

IgG2a

Unconjugated

Protein A affinity chromatography of tissue culture supernatant.

1 mg/ml

Liquid

Supplied in Phosphate Buffered Saline with <0.1% Sodium Azide.

Human CD152, also known as CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4), an inhibitory receptor and negative regulator of T-cell responses. CD152 is a single pass type 1 transmembrane protein belonging to the immunoglobulin superfamily containing a single Ig-v-like domain in the extracellular region.CD152 along with CD28 binds to the co-stimulatory molecules CD80 and CD86. Mouse anti human CD152 antibody, clone BNI3 is able to block ligand binding on the Raji B-cell line and blocks binding of an alternative clone, BNI8 to CTLA-4/Ig in ELISA. Mouse anti Human CD152 antibody, clone BNI3 binds to the same epitope as classified anti CTLA-4 clones 11D4 and 10A8 (Wang et al. In: Leukocyte typing VI 1997 Garland Publishing Inc. pp97-98, Bull World Health Organ. 1997). The cytoplasmic domain of CD152 contains a critical tyrosine at residue 201 phosphorylated by Janus Kinase 2 which subsequently controls surface expression through regulation of CD152 interaction with AP-2 (Shiratori et al. 1997, Chikuma et al. 2000). CD152 is expressed primarily as an intracellular antigen with transport to the cell surface under tight regulation of several molecules including Trim, PLD and TIRC7, CD152 also demonstrates rapid internalization once expressed at the cell surface. CD152 plays a significant role in maintaining tolerance to self antigens and defects in CD152 presentation and expression has been implicated in a number of autoimmune diseases. This antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free fusion protein drug abatacept. It is recommended as the capture reagent, paired with human anti abatacept antibody HCA335 as the detection antibody. Abatacept (Orencia) is a recombinant fusion protein consisting of the extra-cellular domain of human CTLA-4, fused to the modified Fc (hinge, CH2, and CH3 domains) portion of human IgG1.

ALPS5, CD, CD 152, CD152, CD152 antigen, CD152 isoform, Celiac disease 3, CELIAC3, CTLA 4, CTLA-4, CTLA4_HUMAN, Cytotoxic T cell associated 4, Cytotoxic T lymphocyte antigen 4, Cytotoxic T lymphocyte associated 4, Cytotoxic T lymphocyte associated 4, soluble isoform, included, Cytotoxic T lymphocyte associated antigen 4, Cytotoxic T lymphocyte associated antigen 4 short spliced form, Cytotoxic T lymphocyte associated protein 4, Cytotoxic T lymphocyte associated serine esterase 4, Cytotoxic T lymphocyte protein 4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, GRD4, GSE, ICOS, IDDM12, insulin-dependent diabetes mellitus 12, Ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4, OTTHUMP00000216623